Deutsche Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deutsche Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-500	Closed	-$43K	–	4935
2017 Q1	$43K	Buy	500 +396	+381%	+$35.2K	﹤0.01%	4270
2016 Q4	$8K	Sell	104 -520	-83%	-$44.7K	﹤0.01%	4714
2016 Q3	$57K	Buy	+624	New	+$58.8K	﹤0.01%	4158
2015 Q1	–	Sell	-400	Closed	-$36K	–	5147
2014 Q4	$36K	Buy	+400	New	+$33.3K	﹤0.01%	5283
2014 Q1	–	Sell	-450	Closed	-$2K	–	5604
2013 Q4	$2K	Sell	450 -682	-60%	-$46.3K	﹤0.01%	5162
2013 Q3	$6K	Buy	1,132 +732	+183%	+$48.6K	﹤0.01%	5127
2013 Q2	$1K	Buy	+400	New	+$24.9K	﹤0.01%	5234

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's BMRN Position: Q1 2026 in Review

Deutsche Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 40% in Q1 2026, selling an estimated $16.1M and leaving 411,302 shares worth $23.2M. The position accounts for 0.01% of the portfolio, ranked #810.

Deutsche Bank first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $328M in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Deutsche Bank held 411,302 shares of BioMarin Pharmaceuticals worth $23.2M as of Q1 2026.
Deutsche Bank sold 276,356 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $16.1M.
BioMarin Pharmaceuticals made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #810 holding.
Deutsche Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Deutsche Bank's BioMarin Pharmaceuticals position peaked at $328M in Q4 2023.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.